down arrow

Pfizer

  • Market Cap: Mid Cap
  • Industry: Pharmaceuticals & Drugs
  • ISIN: INE182A01018
  • NSEID: PFIZER
  • BSEID: 500680
INR
4,053.50
21.55 (0.53%)
BSENSE

Apr 11, 12:53 PM

BSE+NSE Vol: 10.59 k

  • Price Points
  • Score
  • Mojo Parameters
  • Total Return
  • News and Corporate Actions
  • Key factors
  • Shareholding
  • Financials
  • CompanyCV
stock-summaryCompany CV
About Pfizer Ltd. stock-summary
stock-summary
Pfizer Ltd.
Mid Cap
Pharmaceuticals & Drugs
Pfizer Limited is engaged in manufacturing, marketing, trading and export of pharmaceutical products. The Company offer a portfolio of 150 specialised medicines in 15 therapeutic areas across 4 business categories. It has its own manufacturing facility at Goa and Thane. It has the distinction of being the first pharmaceutical company in India to start clinical research. The Company sells products in nearly 185 countries having 43 manufacturing sites globally.
Company Coordinates stock-summary
Company Details
The Capital 1802/1901 Plot-C70, G Bl Bandra Kurla Cpx Bandra-E Mumbai Maharashtra : 400051
stock-summary
Tel: 91-22-66932000
stock-summary
contactus.india@pfizer.com
Registrar Details
Karvy Computershare Pvt Ltd, Plot No 17-24 , Near Image Hospital,, Reliance Cybervilae,Vithalrao Nagar,, Madhapur, Hyderabad
stock-summary Capital Structure
Capital Structure stock-summary
Present Equity Capital
INR 45.75 Cr
Number of Shares
4.57 Cr
Face Value
INR 10.0
Date
Number
of Shares(Cr)
Equity
Capital (Rs Cr)
Shares Added
Face Value (Rs)
Reason
17-Dec-2014
4.57
45.75
15906292
10
Amalgamation
17-Dec-2014
4.57
45.75
15906292
10
Amalgamation
stock-recommendation Shareholding
Shareholding Snapshotstock-summary
Shareholding Compare (%holding) stock-summary
Majority shareholders

Promoters

Pledged Promoter Holdings

None

Mutual Funds

Held by 21 Schemes (11.3%)

FIIs

Held by 88 FIIs (2.75%)

Promoter with highest holding

Pfizer East India B V (39.75%)

Highest Public shareholder

Life Insurance Corporation Of India (4.07%)

Individual Investors Holdings

12.12%

stock-summary Board of Directors
stock-summary
stock-summary
Management
Designation
Remuneration
Prajeet Nair
Company Sec. & Compli. Officer
0
Uday Khanna
Independent Director
24.0 lacs
Sunil Lalbhai
Independent Director
23.7 lacs
MILIND ANIL PATIL
Executive Director (Finance)
3.6 cr
MEENA GANESH
Independent Director
22.3 lacs
Samir Kazi
Executive Director
3.03 cr
Pradip P Shah
Chairman & Independent Directo
0
Meenakshi Nevatia
Managing Director
0
stock-recommendationRaw Materials
Raw Materials Dashboard stock-summary
Raw Materials
Amount(Rs Cr)
% of RM Cost
 
Icon
No Data Available
stock-recommendation Finished Goods
Finished Goods Dashboard stock-summary
Finished Goods
Amount(Rs Cr)
% of Sales Turnover
Pharmaceutical
1,119.08
53.76%
Traded Goods
911.41
43.79%
Sale of Services (Clinical Research & Support Services)
50.93
2.45%
 
53.76
Pharmaceutical
46.24
Pharmaceutical
43.79
Traded Goods
56.21
Traded Goods
2.45
Sale of Services (Clinical Research & Support Services)
97.55
Sale of Services (Clinical Research & Support Services)
stock-recommendation Stock DNA
Revenue and Profits:
Net Sales:
538 Cr
(Quarterly Results - Dec 2024)
Net Profit:
128 Cr
stock-summary
Industry

Pharmaceuticals & Drugs

stock-summary
Market cap

INR 18,544 Cr (Mid Cap)

stock-summary
P/E

30.00

stock-summary
Industry P/E

33

stock-summary
Dividend Yield

0.87%

stock-summary
Debt Equity

-0.60

stock-summary
Return on Equity

16.41%

stock-summary
Price to Book

4.92